Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study (RELAX-PE)

• ClinicalTrials.gov Identifier: NCT02601846
• Recruitment Status: Completed
• First Posted: November 10, 2015
• Last Update Posted: May 6, 2021
• Sponsor: University Hospital, Geneva
• Collaborators: University Hospital, Brest; European Georges Pompidou Hospital; University Hospital St Luc, Brussels; Centre Hospitalier Universitaire Vaudois; University Hospital, Angers; Centre Hospitalier d'Agen; University Hospital, Clermont-Ferrand
• Information provided by (Responsible Party): Helia Robert-Ebadi, University Hospital, Geneva

Study Description

Brief Summary:

A multicentre multinational prospective management outcome study has recently proven the safety of a diagnostic strategy combining clinical probability assessment with an age-adjusted D-dimer cut-off, defined as a value of (age x 10) in patients > 50 years, for ruling out PE in outpatients, with a very low likelihood of subsequent symptomatic VTE. Moreover, this study showed that such a strategy increased the diagnostic yield of D-dimers, as it allowed ruling out PE without further investigation in a significantly higher proportion of patients than when using standard cut-off, particularly so in patients 75 years or older.

The objective of the present study is to confirm in a prospective cohort of "real life" patients the usefulness of the age-adjusted D-dimer cut-off to rule out PE in patients presenting to the emergency department with suspected PE.

Condition or disease	Intervention/treatment
Pulmonary Embolism	Other: No intervention

Detailed Description:

BACKGROUND

PE diagnostic strategies Pulmonary embolism (PE) is a frequently suspected diagnosis in the emergency room (ER) in patients presenting with shortness of breath and/or chest pain without any obvious cause identified. Historically, PE diagnosis required a pulmonary angiography, a costly and invasive procedure with associated morbidity and even mortality. Over the last 25 years, evolving diagnostic strategies have been developed and widely validated in prospective multicentre management outcome studies, with the aim of confirming or excluding the diagnosis of PE safely enough to avoid realising pulmonary angiography. Nowadays, PE diagnosis therefore relies on diagnostic strategies, including sequential evaluation of clinical probability, measurement of plasma D-dimer levels and most often CT pulmonary angiogram (CTPA), rather than a standalone test.

The initial and essential step is the assessment of pre-test clinical probability, either by gestalt or by validated clinical prediction rules (Wells rule of Geneva score). This initial evaluation separates patients into different groups of PE prevalence, and thus directly influences the negative and positive predictive values of the diagnostic tests used in these patients.

D-dimer measurement Plasma D-dimer measurement has been extensively evaluated for the exclusion of PE in outpatients. The diagnostic usefulness of D-dimers lies in their high sensitivity and hence their capacity to exclude PE when below a certain cut-off ("negative D-dimers") without further investigations. Indeed, in patients with "non-high" clinical probability (low and intermediate groups in a three category score or unlikely group in a dichotomic score), a highly sensitive negative D-dimer test safely excludes PE without additional investigations. Sensitive D-dimer tests include those performed by the ELISA technique (median sensitivity 99%; Vidas®, Stratus®, AxSYM®) and by quantitative latex methods (median sensitivity 96%; STA Liatest®, Tinaquant®). In patients with high clinical probability or likely PE, the negative predictive value of even a highly sensitive D-dimer test will be insufficient to exclude PE. D-dimer measurement is thus not used in these patients.

Performance of D-dimers in elderly patients The specificity of the ELISA and quantitative latex D-dimer tests for venous thromboembolism (VTE) is limited, ranging from 35 to 40%. Indeed, D-dimers increase in various clinical situations, including cancer, infectious or inflammatory states, pregnancy or during post-operative periods, but also with age, leading to reduced specificity of the test in elderly patients. In other words, the probability of having a negative test result is reduced, so that the number of patients needed to test (NNT) to exclude one PE without further investigations is higher. Indeed, whereas PE can be ruled out in presence of non-high clinical probability and negative D-dimers in one out of 3 outpatients presenting to the emergency room with suspected PE, it can be excluded in only one out of 20 patients > 80 years. As current diagnostic strategies for PE include imaging (most often CTPA) in patients with positive D-dimers, lack of specificity of D-dimers in the elderly leads to a high proportion of these patients undergoing CTPA.

Age-adjusted D-dimer cut-off The question of a higher D-dimer cut-off in elderly patients was raised a decade ago, but studies confirming the potential security of such a strategy by retrospectively applying age-adjusted cut-offs to large prospective cohorts of consecutive patients with suspected VTE were published between 2010 and 2012 and confirmed the safety of using age-adjusted cut-offs on an overall population of several thousands of patients.

A progressive age-adjusted D-dimer cut-off (agex10 microg/L in patients > 50 years) was retrospectively derived and validated in a sample of 1712 patients with suspected PE. The retrospective validation study showed that the age-adjusted cut-off could increase by around 20% the number of patients in whom the D-dimer test was considered negative, without increasing the proportion of false-negative results when compared to the standard cut-off (<500 microg/L). The increase in the diagnostic yield of D-dimers was particularly pronounced in patients over 80 years, as the age-adjusted cut-off allowed an increase in the proportion of "negative" D-dimers from 9% to 21%, without any false negative result.

This progressive age-adjusted D-dimer cut-off has been prospectively validated in the ADJUST-PE study, a large multicentre multinational (19 centres in Belgium, France, the Netherlands, and Switzerland) management outcome study published at the beginning of this year. All consecutive patients who presented to the emergency department with clinically suspected PE were assessed by a sequential diagnostic work-up using clinical probability assessment (by one of the two following scores: simplified, revised Geneva score or the two-level Wells score for PE), highly sensitive D-dimer measurement (ELISA or immuno-turbidimetric assays), and CTPA. Patients with a D-dimer level below their age-adjusted cut-off did not undergo further investigations and were thus left without anticoagulant treatment and followed-up for a period of 3 months.

The ADJUST-PE study included a total of 3346 patients with suspected PE, from whom 22 were excluded (D-dimers not performed in 21 and 1 consent withdrawal), leaving 3324 patients included for the analysis. The subgroup of particular interest was of course patients having D-dimer levels between 500 microg/L and their age-adjusted cut-off (n=337). None of these patients was lost to follow-up and 6 patients received therapeutic anticoagulation for another indication than VTE. Of the remaining 331, 7 died and 7 had suspected VTE. Only one of these 14 events was adjudicated as confirmed VTE (nonfatal PE). The so-called "failure-rate" of the age-adjusted cut-off was thus very low at 1 / 331 (0.3%; 95% CI 0.1%-1.7%), so that this strategy can be considered as very safe.

In the ADJUSt-PE study, the overall number of patients ≥ 75 years was 766, of whom 673 had non-high clinical probability (87.9%). Among these 673 patients, the proportion of patients with D-dimer levels <500 microg/L was 43/673 (6.4%; 95% CI 4.8%-8.5%). Additional 157/673 patients (23.3%) had D-dimer levels below their age-adjusted cut-off. This means that among the patients ≥ 75 years with suspected PE and non-high clinical probability, 200/673 (29.7%; 95% CI 26.4%-33.3%) had a "negative" D-dimer result when age-adjusted cut-off was used. After excluding 5 of these patients who received anticoagulation for another indication, none of the remaining 195 patients experienced confirmed VTE during the 3 month follow-up (0.0%; 95% CI 0.0%-1.9%). The diagnostic yield of D-dimers was thus particularly increased by using an age-adjusted cut-off in patients ≥ 75 years, as the number of patients needed to test to exclude one PE diminished from 16 with conventional cut-off to 3.4 with age-adjusted cut-off, a figure that corresponds to the NNT in the general population in previous studies.

Increasing the proportion of patients in whom PE can be ruled out based on clinical probability assessment and D-dimer measurement without further testing is particularly interesting in older patients. Indeed, the higher prevalence of renal failure in this population increases the potential risk of contrast-induced nephropathy related to CTPA or even contra-indicates this test, and ventilation-perfusion lung scan (which can be performed in patients with severe renal failure) provides a high proportion of inconclusive results in older patients. Moreover, ruling out PE based on clinical probability and a simple blood test could contribute to reduce the time spent in the emergency department and the costs related to PE diagnostic work-up. Indeed, a previous study had shown that D-dimer measurement with conventional cut-off was highly cost-saving in patients less than 80 years, but not in patients over 80 years. Using an age-adjusted D-dimer cut-off dramatically increases the proportion of patients in whom PE can be ruled out and is thus highly likely to reduce the costs of PE diagnosis in the emergency department.

Study Design

• Study Type: Observational
• Actual Enrollment: 1507 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study
• Study Start Date: November 2015
• Actual Primary Completion Date: June 2019
• Actual Study Completion Date: June 2019

Groups and Cohorts

Intervention Details:

• Other: No intervention
  This is an observational study, without any specific intervention.

Outcome Measures

Primary Outcome Measures :

1. The incidence of symptomatic thromboembolic events during follow-up in patients with PE excluded based on a negative D-dimer using the age-adjusted cutoff [ Time Frame: Three months ]
   Adjudicated objectively confirmed pulmonary embolism and/or deep vein thrombosis

Secondary Outcome Measures :

1. Additional diagnostic yield of the age-adjusted D-dimer cut-off compared with the standard cut-off of 500µg/L [ Time Frame: Three months ]
   Proportion of patients with a non-high clinical probability and a D-dimer result between 500µg/L and their age-adjusted cut-off value

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

All consecutive patients admitted to the emergency department with suspected PE defined as acute onset of new or worsening shortness of breath or chest pain without any other obvious etiology in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off will be screened for inclusion. Those with non-high probability and negative D-dimer (PE excluded by the non-invasive strategy using "new" D-dimer cut-off) will be included and followed-up for 3 months. The aim of including both patients above and under 50 years of age is to be able to compare the difference in thromboembolic event rates between patients with a D-dimer level between 500 µg/L and their age-ajusted cut-off and those with a D-dimer < 500 µg/L.

Criteria

Inclusion Criteria:

• Consecutive out patients with suspected PE in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off.

Exclusion Criteria:

• Life expectancy less than 3 months.
• Geographic inaccessibility for follow-up.
• Therapeutic anticoagulation for any indication.
• Pregnancy.
• Age less than 18.

Contacts and Locations

Locations

Belgium

Cliniques Universitaires Saint-Luc

Brussels, Belgium

France

Albert Trinh-Duc

Agen, France

Angers Univeristy Hospital

Angers, France

Brest University Hospital

Brest, France

Jeannot Schmidt

Clermont-Ferrand, France

Guy Meyer

Paris, France

Switzerland

Hôpital Fribourgeois HFR

Fribourg, Switzerland

Geneva University Hospitals

Geneva, Switzerland

Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland

Groupement Hospitalier de l'Ouest Lémanique

Nyon, Switzerland

Sponsors and Collaborators

University Hospital, Geneva

University Hospital, Brest

European Georges Pompidou Hospital

University Hospital St Luc, Brussels

Centre Hospitalier Universitaire Vaudois

University Hospital, Angers

Centre Hospitalier d'Agen

University Hospital, Clermont-Ferrand

Investigators

• Principal Investigator: Helia Robert-Ebadi, MD; Geneva University Hospitals and Faculty of Medicine

More Information

Publications:

Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014 Mar 19;311(11):1117-24. doi: 10.1001/jama.2014.2135. Erratum in: JAMA. 2014 Apr 23-30;311(16):1694.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Robert-Ebadi H, Robin P, Hugli O, Verschuren F, Trinh-Duc A, Roy PM, Schmidt J, Fumeaux T, Meyer G, Hayoz D, Carron PN, Salaun PY, Sarasin F, Rutschmann O, Le Gal G, Righini M. Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism: A Multinational Prospective Real-Life Study (the RELAX-PE Study). Circulation. 2021 May 4;143(18):1828-1830. doi: 10.1161/CIRCULATIONAHA.120.052780. Epub 2021 May 3.

• Responsible Party: Helia Robert-Ebadi, Principal Investigator, University Hospital, Geneva
• ClinicalTrials.gov Identifier: NCT02601846
• Other Study ID Numbers: Geneva 15-010
• First Posted: November 10, 2015
• Last Update Posted: May 6, 2021
• Last Verified: May 2021

Additional relevant MeSH terms:

Pulmonary Embolism; Embolism; Emergencies; Disease Attributes; Pathologic Processes; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Lung Diseases; Respiratory Tract Diseases